BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 2345-2350

  Sideris, Michail ^a   Adams, Katie ^a   Moorhead, Jane ^a   Diaz Cano, Salvador ^a   Bjarnason, Ingvar ^a   Papagrigoriadis, Savvas ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

BRAFV600E; Colorectal cancer; Iron deficiency anaemia; KRAS; Molecular biomarkers

Indexed keywords

B RAF KINASE; HEMOGLOBIN; K RAS PROTEIN; BRAF PROTEIN, HUMAN;

AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; LYMPH VESSEL METASTASIS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM ASSESSMENT; ADULT; COLORECTAL TUMOR; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; COLORECTAL NEOPLASMS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84928406425     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Herzig DO and Tsikitis VL: Molecular markers for colon diagnosis, prognosis and targeted therapy. J Surg Oncol 111(1): 96-102, 2014.
2. Thiel A and Ristimaki A: Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol 3: 272, 2013.
3. Deschoolmeester V, Baay M, Specenier P, Lardon F and Vermorken JB: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 15(7): 699-731, 2010.
4. Pino MS and Chung DC: The chromosomal instability pathway in colon cancer. Gastroenterology 138(6) : 2059-2072, 2010.
5. Lynch HT, Smyrk T and Lynch JF: Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from pedigree anecdote to molecular genetic confirmation. Oncology 55(2): 103-108, 1998.
6. Boland CR and Goel A: Microsatellite instability in colorectal cancer. Gastroenterology 138(6) : 2073-2087 e2073, 2010.
7. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL and Fuchs CS: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58(1): 90-96, 2009.
8. Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruine AP, Carvalho B, Meijer GA, Schouten LJ, van den Brandt PA, Weijenberg MP and van Engeland M: A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol 24(8): 2048-2056, 2013.
9. Lievre A, Rouleau E, Buecher B and Mitry E: [Clinical significance of BRAF mutations in colorectal cancer]. Bull Cancer 97(12) : 1441-1452, 2010.
10. Roa I, Game A, Bizama C and Schalper K: [ BRAF gene mutation in wild-type KRAS patients with colorectal cancers]. Rev Med Chil 142(1): 55-60, 2014.
11. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS and Ogino S: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105(15) : 1151-1156, 2013.
12. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, Baron JA, Ahnen DJ, Win AK, Potter JD and Newcomb PA: BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 21(10): 1792-1798, 2012.
13. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T and Omata M: Functional analysis of mutations within the kinase activation segment of B-RAF in human colorectal tumors. Cancer Res 63(23): 8132-8137, 2003.
14. Millington GW: Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54). Clin Exp Dermatol 38(2): 222-223, 2013.
15. Mao C, Liao RY, Qiu LX, Wang XW, Ding H and Chen Q: BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 38(4) : 2219-2223, 2011.
16. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F and Russo A: Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 36 Suppl 3 : S56-61, 2010.
17. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE and Thibodeau SN: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14(11): 3408-3415, 2008.
18. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O and Desai J: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20): 4623-4632, 2011.
19. Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O and Tomlinson I: Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229(3): 441-448, 2013.
20. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E and Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28(3) : 466-474, 2010.
21. Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q and Fu WL: BRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 9(3): e90607, 2014.
22. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M and Engelman JA: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2(3) : 227-235, 2012.
23. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A and Bernards R: Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 483(7387) : 100-103, 2012.
24. Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L and Wang JP: The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 8(6): e65995, 2013.
25. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V and Souglakos J: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 6(1): e15980, 2011.
26. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, Rutegard J and Palmqvist R: The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108(10) : 2153-2163, 2013.
27. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M and Di Nicolantonio F: BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Mol Cancer Ther 12(12) : 2950-2961, 2013.
28. Ciombor KK, Wu C and Goldberg RM: Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med 68 : 83-95, 2014.
29. Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M and Church JM: BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 55(2) : 128-133, 2012.
30. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK and Slattery ML: Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res 65(14): 6063-6069, 2005.
31. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA and Fuchs CS: Prognostic significance and molecu lar associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 27(27) : 4591-4598, 2009.
32. Clancy C, Burke JP, Kalady MF and Coffey JC: BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 15(12): e711-718, 2013.
33. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA and Berger BM: Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370(14): 1287-1297, 2014.
34. Lee JK and Chan AT: Molecular prognostic and predictive markers in colorectal cancer: current ctatus. Curr Colorectal Cancer Rep 7(2) : 136-144, 2011.
35. Corso G, Pascale V, Flauti G, Ferrara F, Marrelli D and Roviello F: Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. Eur J Hum Genet 21(12): 1383-1388, 2013.
36. Grade M, Wolff HA, Gaedcke J and Ghadimi BM: The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg 397(4): 543-555, 2012.
37. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR and Buchanan DD: Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 26(6) : 825-834, 2013.